EFECT OF METFORMIN STIMULATED ENDOTHELIAL NOS ON LYMPHOCYTIC PROLIFERATION

Abstract

Undeniable is the fact that NO is involved in the pathogenesis and
control of infectious diseases, has an effect on tumors, autoimmune processes and
chronic degenerative diseases. However, this transmitter has a direct dose
dependence, the effects of which can be diametrically opposed. Despite a large amount
of information on the effects of NOS on immune cells, the issue of the effects of certain
types of it, namely eNOS, on the proliferative function of the lymphocyte cell immunity
cell remains open. The study used the Metformine (Mf), which is a trigger for the
production of NO, namely endothelial synthase nitrogen oxide (eNOS). This
gastransponder was chosen as it has been used for therapeutic purposes for decades
and has a bulky evidence base of research. Mf in the form of tablets Mefarmil 500 mg
(“Kievmedpreparat”) was used as the eNOS synthesis trigger. The study was
conducted on white BALB mice weighing 25-30 g. All animals were divided into four
groups: control group, and three experimental ones with Mf concentrations: 0,7; 1,1;
2,0 mg per individual.
The research lasted 20 days, the drug was administered at the same time. The
red bone marrow was taken from the femoral bone by puncture method, blood was
taken from the abdominal cavity. The smears were dyed with the Romanovsky-Gimse
dye. Mice have been shown to affect the number of lymphocytes under various
metformin concentrations (eNOS). Namely, a decrease in the concentration of 0,7 mg
and an increase in lymphocytes at doses of 1,1 and 2,0 mg of metformin compared
with control. The dose-dependent effect of eNOS on the selection of prolymphoblasts
and lymphoblasts, reduction of blasts in group 2, and reduction of proliferoblasts in
the group 1 and lymphoblasts of group 3, and increase of lymphoblasts in group 1 and
prolymphoblasts of group 3 were established.
Keywords: eNOS, metformin, lymphocyte, proliferation.